Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Please indicate which comment is of concern and why. Your comments will be sent to our moderator for review.

Report comment to moderator

MandatoryRequired fields.


Taiwo Owatemi: 'Like every pharmacist in the country, I’ve been frustrated by medicines shortages'


For the past 3 years I have been involved with a European group called COST which is researching the causes of shortages of medicines and how best to manage shortages. One of the causes of shortages is "manufacturing and quality issues" as indicated by Taiwo. Other causes are "supply chain" and "regulatory" issues but the main one is "economics". Manufacturing issues are frequently caused by problems with the active ingredient, and for generic products, the majority of active raw materials, particularly antibiotics and antineoplastics are currently synthesised in China and India. We believe that there would be numerous healthcare and socioeconomic benefits if the production base of medicinal products returned to the European region. However, it must also be recognised that this would have a significant INCREASE in the cost of production of medicines and the topic needs to be discussed within the broader perspective of medicines pricing and supply. Jane Nicholson B.Pharm. FRPharm S.FTOPRA

Posted date

15 FEB 2020

Posted time



Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.